



doseology

# Doseology To Attend CHFA NOW Show, Sept 17-18

VERNON, BC, Sept. 13, 2022 /CNW/ - **Doseology Sciences Inc.** (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) ("Doseology" or the "Company"), a life sciences company focused on mental health and wellness, is excited to announce that it is attending the CHFA NOW trade show in Toronto from September 17 to 18.

CHFA NOW ([chfanow.ca](http://chfanow.ca)) is a Canadian trade show that focuses on the natural, organic, and wellness industry. The event takes place over the course of four days twice a year in Vancouver (April) and Toronto (September). This event is an opportunity for Doseology to introduce its brand to potential retail partners, network with over 3,000 attendees and 1,000 exhibiting companies\*, and gain market insights.

The 2022 Toronto CHFA NOW trade show is taking place in the Enercare Centre at Exhibition Place from September 15 to 18. Doseology will be attending the trade show from 10 am to 5 pm ET on September 17 to 18. The Company will be exhibiting its functional mushroom line at booth #2032.

Doseology will be showcasing its line of functional mushroom supplements, which includes:

- **Wake:** Blend of [lion's mane mushroom](#) fruiting bodies, yerba mate, and vitamins B6 and B12 to promote wakefulness and to support cognitive performance (tincture, 28 servings).
- **Elevate:** Blend of lion's mane mushroom fruiting bodies, ginger root, and vitamin B3 to elevate mood and enhance cognitive clarity (tincture, 28 servings).
- **Boost:** Blend of shiitake fruiting bodies and turmeric to provide the body with potent antioxidants to strengthen and support immunity (tincture, 28 servings).
- **Sleep:** Blend of reishi mushroom fruiting bodies, German chamomile, and melatonin to promote relaxation and sleep onset (tincture, 28 servings).

On Behalf of the Board of Directors

Ralph Olson  
Chief Executive Officer  
Doseology Sciences Inc.

\*Based on stats from the previous CHFA Toronto show – September 2019.

**About Doseology Sciences ([CSE: MOOD](#)) ([OTCQB: DOSEF](#)) ([FSE: VU7](#))**

Doseology Sciences Inc. is building a progressive brand focused on mental health and wellness through cultivation, extraction and innovative nutraceutical and pharmaceutical products. Doseology aims to make a meaningful impact on the mental health pandemic by utilizing and developing functional fungi and plant-derived drugs. With a vertically integrated approach, Doseology intends to process and distribute products at its facilities in Vernon, British Columbia, in accordance with applicable laws to ensure safe and high-quality production. Doseology's medicinal mushroom products, including tinctures, powders and supplements, are available on [doseology.com](http://doseology.com).

## Forward-Looking Statements

This press release contains statements that constitute "forward-looking information" within the

meaning of applicable securities laws. Forward-looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on [SEDAR](#).

No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company's securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

**The CSE does not accept responsibility for the adequacy or accuracy of this release.**

SOURCE Doseology Sciences Inc.

View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/September2022/13/c4266.html>

%SEDAR: 00051102E

**For further information:** Investor Relations: [investor@doseology.com](mailto:investor@doseology.com); General Inquiries: [hello@doseology.com](mailto:hello@doseology.com), Telephone: 236-349-0064, Website: [doseology.com](http://doseology.com)

CO: Doseology Sciences Inc.

CNW 09:00e 13-SEP-22